Macrolide antibiotics (MACs) such as clarithromycin (CAM) and roxithromycin (RXM) provide not only anti-bacterial activity but also anti-inflammatory effects. Several recent studies have reported successful treatments of rheumatoid arthritis (RA) and organizing pneumonia (OP) using CAM as an antiinflammatory drug.
findings were as follows: white blood cell count, 6,280/μL (normal range, 4,000 to 9,800/μL); C-reactive protein (CRP), 60.5 mg/L (normal value, <3 mg/L); and rheumatoid factor, 83 U/ mL (normal value, <15 U/mL). Bone roentgenogram revealed periarticular osteopenia in the bilateral knees and wrist joints. High resolution chest computed tomography revealed airspace consolidation and ground-glass opacity predominantly in the right lower lung field compatible with OP ( Fig. 1) . Because of the symmetric polyarthritis of the small joints in both hands and feet together with morning stiffness and the positive result of rheumatic factor, a diagnose of RA was made according to the American College of Rheumatology criteria.
5) It was thought that OP was associated with RA. The clinical course is as follows (Fig. 2) . We evaluated RA activity, taking advantage of disease activity score (DAS)28-CRP. The DAS28-CRP considers 28 tender and swollen joint counts, general health (GH; patient assessment of disease activity using a 100 mm visual analogue scale with 0=best, 100=worst), plus levels of CRP (mg/L Because his DAS28-CRP was 6.15, we initiated a treatment with salazosulfapyridine (1 g/day) and loxoprofen (180 mg/day). Although this treatment was effective, it was discontinued due to the development of drug eruption. The patient decided not to receive either methotrexate or leflunomide because of several reports of interstitial pneumonia cases caused by these two agents. At the same time, he could not afford either tumor necrosis factor-α blocking agents or an interleukin (IL)-6-receptor due to their high costs. As an alternative, the patient received prednisolone (PSL) (5 mg/day), celecoxib (CEL) (200 mg/day) and CAM (400 mg/day), in the expectation of their anti-inflammatory effects on RA and OP.
1-3)
After six months of treatment with PSL, CEL and CAM, arthralgia and articular swellings, except for that of left wrist joint, substantially improved. His DAS28-CRP indicated low disease activity. OP also improved simultaneously. Since the left-handed patient did underappreciate improvement on the sign and symptom of the left wrist, TAC (1.5 mg/day) was added, and thereafter arthralgia and articular swelling of the left wrist improved only moderately. We regarded the optimal trough levels of TAC as 5.0 to 10.0 ng/mL; however, the trough levels of TAC (1.5 mg/day) were low (4.1 ng/mL). Therefore, instead of increasing the dosage of expensive TAC, the dosage of CAM that is assumed to raise blood TAC concentrations was increased to 800 mg/day. Two weeks after enhancing the CAM (800 mg/day) treatment, the trough levels of TAC increased to 7.1 ng/mL, and 6 weeks after initiating a new dosage of the CAM (800 mg/day) treatment, arthralgia and articular swellings were almost completely resolved. His DAS28-CRP level indicated remission. 
1)
Because Ogrendik hypothesized that oral anaerobic bacteria could play an important role in the pathogenesis of RA, 9) the efficacy of CAM for RA may be derived from its antibacterial activity as well as its anti-inflammatory effects. Regarding CAM treatment for RA, Ogrendik reported that treatment with CAM 500 mg daily for 6 months improved the signs and symptoms in patients with early active RA. 1) Regarding RXM treatment for RA, Ogrendik reported that treatment with RXM 300 mg daily for 3 months improved DAS 28.
2) Similarly, Stover et al.
reported several cases of OP were treated successfully using MACs in consideration of their anti-inflammatory effects.
3) In the present case, the treatment with PSL (5 mg/day) and CAM (400 mg/day) demonstrated being effective for OP and RA, to a certain extent; however, the RA activity was not completely suppressed. In order to suppress the RA activity further, TAC was carefully added with monitoring blood TAC concentrations. For the purpose of raising blood TAC concentrations, the dosage of CAM was effectively increased. With regard to the pharmacokinetic interaction between CAM and TAC, studies have shown that CAM causes an increase of blood TAC concentration by suppressing TAC metabolism. 10) Researches have shown that TAC is primarily metabolized by cytochrome P450 (CYP)3A with oral administration and inter-individually varied widely on blood concentration. Levels are knowingly affected by the fat content and genetic polymorphisms of CYP3A5. 11) As CAM is a potent CYP3A inhibitor, co-administration of both CAM and TAC leads to significant pharmacokinetic interaction. As a result, CAM raises blood TAC concentrations by suppressing TAC metabolism via CYP3A inhibition. 10) This allowed the RA activity to be completely controlled under optimal blood TAC concentrations. According to recent reports of successful treatments in lupus nephritis and adult-onset Still's disease, CAM was added to increase blood concentration of TAC. 12, 13) Based on these findings, a treatment with PSL, CAM and TAC with optimal blood concentrations, is thought to be effective for RA. When optimal blood concentrations of TAC are guaranteed, CAM may be useful.
In conclusion, we report a case of uncontrolled RA with concomitant OP successfully treated with PSL, CAM, and TAC. Further research is necessary to substantiate our findings until this treatment is incorporated into mainstream.
